Net income up 23% at Schering AG as Betaferon sales stay strong
Schering AG of Germany says that net sales increased 7% to 3.58 billioneuros ($3.22 billion) for the first nine months of 2001 and net income improved 23% to 331 million euros. Operating profit, however, advanced just 4% to 494 million euros, reflecting investments in its new product launches both in the USA and Europe, the company notes.
The multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b) continued to be Schering's largest-selling product, with turnover up 12% to 491 million euros for the six months. The firm notes that, in the USA, the success of Betaferon and the chronic lymphocytic leu-kemia drug Fludara (fludarabine), with sales up 22% at 100 million euros), enabled Schering to cushion the fall of Betapace (sotalol), turnover of which fell 49% to 77 million euros.
Strong start for Campath
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze